Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Can J Cardiol

Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center, Depatment of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.

Published: September 2006

Background: A wide variety of pathological conditions have been shown to result in cardiac remodelling and myocardial dysfunction. However, the mechanisms of transition from adaptive to maladaptive alterations, as well as those for changes in cardiac performance leading to heart failure, are poorly understood.

Observations: Extensive studies have revealed a broad spectrum of progressive changes in subcellular structures and function, as well as in signal transduction and metabolism in the heart, among different cardiovascular disorders. The present review is focused on identifying the alterations in molecular and biochemical structure of myofibrils (myofibrillar remodelling) in hypertrophied and failing myocardium in different types of heart diseases. Numerous changes at the level of gene expression for both contractile and regulatory proteins have already been reported in failing hearts and heart diseases; these changes are potential precursors for heart failure such as cardiac hypertrophy and cardiomyopathies. Myofibrillar remodelling, as a consequence of proteolysis, oxidation, and phosphorylation of some functional groups in both contractile and regulatory proteins in hearts failing due to different etiologies, has also been described.

Conclusions: Although myofibrillar remodelling appears to be associated with cardiac dysfunction, alterations in both contractile and regulatory proteins are dependent on the type and stage of heart disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570240PMC
http://dx.doi.org/10.1016/s0828-282x(06)70315-4DOI Listing

Publication Analysis

Top Keywords

heart failure
12
myofibrillar remodelling
12
contractile regulatory
12
regulatory proteins
12
cardiac hypertrophy
8
heart diseases
8
heart
7
cardiac
5
myofibrillar
4
myofibrillar remodeling
4

Similar Publications

Role of PGC-1α in the proliferation and metastasis of malignant tumors.

J Mol Histol

January 2025

Department of Thoracic Surgery, Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.

Malignant tumors are among the major diseases threatening human survival in the world, and advancements in medical technology have led to a steady increase in their detection rates worldwide. Despite unique clinical presentations across the spectrum of malignancies, treatment modalities generally adhere to common strategies, encompassing primarily surgical intervention, radiation therapy, chemotherapy, and targeted treatments. Uncovering the genetic elements contributing to cancer cell proliferation, metastasis, and drug resistance remains a pivotal pursuit in the development of novel targeted therapeutics.

View Article and Find Full Text PDF

Cardiomyocytes can be implanted to remuscularize the failing heart. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques.

View Article and Find Full Text PDF

Background: Assessing the relative performance of machine learning (ML) methods and conventional statistical methods in predicting prognosis in heart failure (HF) still remains a challenging research field.

Methods: The primary outcome was three-year mortality. The following 5 machine learning approaches were used for modeling: Random Forest (RF), Gradient Boosting, Extreme Gradient Boosting (XGBoost), Support Vector Machine, and Multilayer perceptron.

View Article and Find Full Text PDF

Acute myocardial infarction (AMI) remains one of the most common causes for cardiogenic shock (CS), with high inpatient mortality (40-50 %). Studies have reported the use of pulmonary artery catheters (PACs) in decompensated heart failure, but contemporary data on their use to guide management of AMI-CS and in different SCAI stages of CS are lacking. We investigated the association of PACs and clinical outcomes in AMI-CS.

View Article and Find Full Text PDF

Introduction: Cardiogenic shock (CS) is marked by substantial morbidity and mortality. The two major CS etiologies include heart failure (HF) and acute myocardial infarction (AMI). The utilization trends of mechanical circulatory support (MCS) and their clinical outcomes are not well described.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!